Columbus Circle Investors Sells 10,930 Shares of Zoetis (ZTS)

Columbus Circle Investors reduced its position in Zoetis (NYSE:ZTS) by 4.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 255,365 shares of the company’s stock after selling 10,930 shares during the quarter. Columbus Circle Investors owned about 0.05% of Zoetis worth $21,326,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Navellier & Associates Inc acquired a new position in Zoetis in the 4th quarter valued at $606,000. Lombard Odier Asset Management Switzerland SA raised its stake in Zoetis by 13.8% in the 4th quarter. Lombard Odier Asset Management Switzerland SA now owns 279,676 shares of the company’s stock valued at $20,148,000 after purchasing an additional 34,000 shares during the last quarter. Amalgamated Bank grew its holdings in Zoetis by 9.5% in the 4th quarter. Amalgamated Bank now owns 64,901 shares of the company’s stock valued at $4,675,000 after buying an additional 5,633 shares in the last quarter. Westwood Holdings Group Inc. grew its holdings in Zoetis by 13.3% in the 4th quarter. Westwood Holdings Group Inc. now owns 65,133 shares of the company’s stock valued at $4,692,000 after buying an additional 7,632 shares in the last quarter. Finally, We Are One Seven LLC purchased a new stake in Zoetis in the 4th quarter valued at $120,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

In other news, insider Kristin C. Peck sold 4,877 shares of the stock in a transaction on Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the transaction, the insider now directly owns 42,652 shares in the company, valued at approximately $3,559,735.92. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Heidi C. Chen sold 37,453 shares of the stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $81.02, for a total value of $3,034,442.06. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 117,829 shares of company stock valued at $9,626,877. Company insiders own 0.35% of the company’s stock.

NYSE ZTS opened at $82.95 on Friday. The firm has a market cap of $40.17 billion, a PE ratio of 34.56, a price-to-earnings-growth ratio of 1.83 and a beta of 0.97. The company has a debt-to-equity ratio of 2.51, a current ratio of 4.27 and a quick ratio of 2.83. Zoetis has a twelve month low of $82.05 and a twelve month high of $83.07.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.35 billion. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.53 EPS. equities analysts expect that Zoetis will post 3.06 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date is Thursday, July 19th. Zoetis’s dividend payout ratio is presently 20.83%.

Several analysts have issued reports on ZTS shares. Craig Hallum restated a “buy” rating and issued a $94.00 target price (up from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. Cowen set a $85.00 target price on Zoetis and gave the company a “buy” rating in a report on Thursday, February 15th. Citigroup restated a “buy” rating and issued a $98.00 target price (up from $85.00) on shares of Zoetis in a report on Thursday, April 19th. Bank of America upped their target price on Zoetis from $80.00 to $87.00 and gave the company a “buy” rating in a report on Friday, February 16th. Finally, Jefferies Group set a $97.00 target price on Zoetis and gave the company a “buy” rating in a report on Monday, February 26th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company. Zoetis presently has a consensus rating of “Buy” and an average target price of $82.67.

Zoetis Company Profile

Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply